UK markets close in 1 hour
  • FTSE 100

    7,427.05
    +124.31 (+1.70%)
     
  • FTSE 250

    19,955.07
    +266.05 (+1.35%)
     
  • AIM

    958.88
    +11.71 (+1.24%)
     
  • GBP/EUR

    1.1819
    +0.0037 (+0.31%)
     
  • GBP/USD

    1.2486
    +0.0011 (+0.09%)
     
  • BTC-GBP

    23,997.22
    +50.61 (+0.21%)
     
  • CMC Crypto 200

    667.50
    -5.87 (-0.87%)
     
  • S&P 500

    3,911.38
    +10.59 (+0.27%)
     
  • DOW

    31,257.32
    +4.19 (+0.01%)
     
  • CRUDE OIL

    112.50
    +0.29 (+0.26%)
     
  • GOLD FUTURES

    1,833.50
    -7.70 (-0.42%)
     
  • NIKKEI 225

    26,739.03
    +336.19 (+1.27%)
     
  • HANG SENG

    20,717.24
    +596.56 (+2.96%)
     
  • DAX

    14,068.77
    +186.47 (+1.34%)
     
  • CAC 40

    6,332.93
    +60.22 (+0.96%)
     

ResMed Upgraded By BofA and JPMorgan

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

By Sam Boughedda

Investing.com — Shares of California-based medical device company ResMed Inc (NYSE:RMD) bumped up 0.4% after upgrades by analysts at BofA and JP Morgan on Monday.

BofA analyst Lyanne Harrison upgraded ResMed to neutral from underperform, raising the price target to $250 from $229.

Harrison said the firm upgraded the stock due to valuation. "RMD stock has retreated to $235/shr, and is now 20% below its Sep21 peak," said the analyst.

"The likelihood of extended chip shortage prevents us from having a more positive view. Longer term, we expect RMD's recent market share gains to unwind as Philips (PHIA) supply returns," she added.

Koninklijke Philips NV ADR (NYSE:PHG), which moved from consumer products to healthcare, has recently been hit by chip shortages and a product recall.

Meanwhile, JPMorgan (NYSE:JPM) analyst David Low upgraded ResMed to overweight from neutral, also increasing the price target to $270 from $260. Low said 2022 is "a year of opportunity" for ResMed and expects the company to take advantage of competitor Philip's recall.

Also acknowledging that Philips will recover, the JPM analyst said ResMed has "both the product range and sales force to ensure it holds onto material share gains."

Related Articles

ResMed Upgraded By BofA and JPMorgan

Shopify eases concerns over fulfillment network changes, shares rebound

U.S. to move faster to address unfair airline consumer practices -sources

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting